Science · Open for opinions
Will the FDA or EMA authorize a human clinical trial for epigenetic therapy against hepatitis B by October 31, 2026?
Measures the regulatory progress of the new epigenetic editing technique described in Nature. 57 opinions, 65% No
- Yes — 35%
- No — 65%
Deadline: October 31, 2026 at 11:59 PM UTC · 57 opinions
Resolution rules
Measures the regulatory progress of the new epigenetic editing technique described in Nature.
Source: www.nature.com
Frequently asked questions about this event
How is this event resolved?
Janela de apuração: de 22/09/2026 (00:00, horário de Brasília) até 31/10/2026 (23:59). Fatos, anúncios ou eventos anteriores ao início da janela não contam. Resolve como 'Sim' se a FDA (EUA) ou a EMA (União Europeia) aprovar pedido de Investigational New Drug (IND) ou ensaio clínico de edição epigenética contra o vírus da hepatite B até 31/10/2026, registrado no ClinicalTrials.gov, fda.gov ou ema.europa.eu. Caso contrário, resolve como 'Não'.
How are points scored?
Points depend on the share of votes your side had when you gave your opinion. Being right earns 100 minus that share. Being wrong costs that share.
Right now No has 65% of the votes: an opinion on it that turns out right earns about 35 points, a wrong one costs about 65.